98 related articles for article (PubMed ID: 38608646)
1. Therapy-Related Myeloid Neoplasm: Biology and Mechanistic Aspects of Malignant Progression.
Travaglini S; Marinoni M; Visconte V; Guarnera L
Biomedicines; 2024 May; 12(5):. PubMed ID: 38791019
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.
Yin CC; Medeiros LJ; Bueso-Ramos CE
Int J Lab Hematol; 2010 Oct; 32(5):461-76. PubMed ID: 20626469
[TBL] [Abstract][Full Text] [Related]
3. Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?
Heuser M
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):24-32. PubMed ID: 27913458
[TBL] [Abstract][Full Text] [Related]
4. Myeloid neoplasms post cytotoxic therapy: epidemiology, pathogenesis outcomes, prognostic factors, and treatment options.
Ma J; Wang Y
Ann Med; 2024 Dec; 56(1):2329132. PubMed ID: 38608646
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.
Nardi V; Winkfield KM; Ok CY; Niemierko A; Kluk MJ; Attar EC; Garcia-Manero G; Wang SA; Hasserjian RP
J Clin Oncol; 2012 Jul; 30(19):2340-7. PubMed ID: 22585703
[TBL] [Abstract][Full Text] [Related]
6. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
[TBL] [Abstract][Full Text] [Related]
7. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
8. [Treatment responses, outcomes, and prognostic factors associated with them in patients with secondary acute myeloid leukemia].
Ma L; Zhao T; Chen YY; Jiang H; Xu LP; Zhang XH; Wang Y; Sun YQ; Mo XD; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):124-131. PubMed ID: 36948866
[No Abstract] [Full Text] [Related]
9. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
10. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
Diamond B; Ziccheddu B; Maclachlan K; Taylor J; Boyle E; Ossa JA; Jahn J; Affer M; Totiger TM; Coffey D; Chandhok N; Watts J; Cimmino L; Lu SX; Bolli N; Bolton K; Landau H; Park JH; Ganesh K; McPherson A; Sekeres MA; Lesokhin A; Chung DJ; Zhang Y; Ho C; Roshal M; Tyner J; Nimer S; Papaemmanuil E; Usmani S; Morgan G; Landgren O; Maura F
Blood; 2023 May; 141(19):2359-2371. PubMed ID: 36626250
[TBL] [Abstract][Full Text] [Related]
11. Epidemiologic outlook of therapy-related myeloid neoplasms and selection of high-risk patients: A Korean nationwide study.
Ha H; Kim HJ; Park JH; Shin A; Lee KN; Han K; Lee NR; Hong J
Cancer; 2022 Nov; 128(21):3888-3896. PubMed ID: 36069361
[TBL] [Abstract][Full Text] [Related]
12. In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge.
Stefaniuk P; Szymczyk A; Podhorecka M
J Clin Med; 2022 Jul; 11(15):. PubMed ID: 35893374
[TBL] [Abstract][Full Text] [Related]
13. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
Khoury JD; Solary E; Abla O; Akkari Y; Alaggio R; Apperley JF; Bejar R; Berti E; Busque L; Chan JKC; Chen W; Chen X; Chng WJ; Choi JK; Colmenero I; Coupland SE; Cross NCP; De Jong D; Elghetany MT; Takahashi E; Emile JF; Ferry J; Fogelstrand L; Fontenay M; Germing U; Gujral S; Haferlach T; Harrison C; Hodge JC; Hu S; Jansen JH; Kanagal-Shamanna R; Kantarjian HM; Kratz CP; Li XQ; Lim MS; Loeb K; Loghavi S; Marcogliese A; Meshinchi S; Michaels P; Naresh KN; Natkunam Y; Nejati R; Ott G; Padron E; Patel KP; Patkar N; Picarsic J; Platzbecker U; Roberts I; Schuh A; Sewell W; Siebert R; Tembhare P; Tyner J; Verstovsek S; Wang W; Wood B; Xiao W; Yeung C; Hochhaus A
Leukemia; 2022 Jul; 36(7):1703-1719. PubMed ID: 35732831
[TBL] [Abstract][Full Text] [Related]
14. Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML.
Uy GL; Newell LF; Lin TL; Goldberg SL; Wieduwilt MJ; Ryan RJ; Faderl S; Lancet JE
Blood Adv; 2022 Sep; 6(17):4989-4993. PubMed ID: 35443022
[No Abstract] [Full Text] [Related]
15. The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation.
Gramegna D; Bertoli D; Cattaneo C; Almici C; Re A; Belotti A; Borlenghi E; Lanzi G; Archetti S; Verardi R; Brugnoni D; Sciumè M; Daffini R; Roccaro AM; Tucci A; Rossi G
Ann Hematol; 2022 Jun; 101(6):1227-1237. PubMed ID: 35380239
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
